

Supplementary Online Content

Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I. Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial. *JAMA Ophthalmol*. Published online May 14, 2020. doi:10.1001/jamaophthalmol.2020.1539


eFigure 1. Trial Profile-Patient Selection Flowchart

eFigure 2. Kaplan-Meier Curves for Time to Adverse Event by Response Group in Accordance With Extended Treatment Breaks


eFigure 3. Demonstration of the Upper 10% of Vismodegib Adverse Events

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Trial Profile-Patient Selection Flowchart



eFigure 2. Kaplan-Meier Curves for Time to Adverse Event by Response Group in Accordance With Extended Treatment Breaks



The figure compares the four-response group and for each group demonstrate the difference between treatment regimens in regard to break vs no break treatment.

eFigure 3. Demonstration of the Upper 10% of Vismodegib Adverse Events

